A novel Posaconazole oral formulation using spray dried solid dispersion technology: in-vitro and in-vivo study
Authors:
- 11 November 2023
- journal article
- research article
- Published by Springer Nature in Drug Delivery and Translational Research
- Vol. 14 (5) , 1253-1276
Abstract
SD (solid dispersion) technology is one of the well-recognized solubility enhancement methods; but the use of versatile carriers in ASD (amorphous SD) to achieve the added advantage of modified release along with solubility improvement is an emerging area of exploration. Spray drying is a widely used technology with excellent scalability and product attributes. The SD carriers explored were Soluplus®, possessing excellent solubilization properties that may enhance bioavailability and is suitable for innovative processing, and Gelucire 43/01, a lipid polymer utilized in a non-effervescent-based floating gastro-retentive DDS for the modified release of API. The CPPs of spray drying were screened during preliminary trials, and the formulation variables were optimized using a 32 Full Factorial Design. All nine batches were evaluated for % yield, % drug content, flow properties, floating behavior, saturation solubility, and in-vitro drug release in 0.1 N HCl. The optimized batch characterized based on DSC (differential scanning calorimetry) and PXRD (powder X-ray diffraction) confirmed the amorphous nature of entrapped drug in SDD (spray-dried dispersion). Particle size analysis and SEM (scanning electron microscopy) demonstrated micron size irregular shaped particles. Residual solvent analysis by GCMS-HS confirmed the elimination of organic solvents from SDD. The optimized batch was found stable after 6 months stability study as per ICH guidelines. In-vivo roentgenography study in New Zealand white rabbit showed the residence of SDD in gastric environment for sufficient time. The pharmacokinetic study was performed in male Sprague–Dawley rats to determine the bioavailability of developed SDD based product in fasting and fed conditions, and to compare the data with marketed Noxafil formulation. The current research is focused on the development of a novel ternary SDD (spray-dried dispersion)-based gastro-retentive formulation for an anti-fungal drug Posaconazole. Graphical Abstract The study included development of a novel oral formulation of Posaconazole based on Spray Drying Solid Dispersion Technology using novel carriers enabling gastro-retention and solubility enhancement.Keywords
This publication has 55 references indexed in Scilit:
- Revealing facts behind spray dried solid dispersion technology used for solubility enhancementSaudi Pharmaceutical Journal, 2015
- Preparation and evaluation of dual-mode floating gastroretentive tablets containing itraconazoleDrug Delivery, 2013
- Preparation and characterization of emulsified solid dispersions containing docetaxelArchives of Pharmacal Research, 2011
- In Vitro Release Kinetics and Bioavailability of Gastroretentive Cinnarizine Hydrochloride TabletAAPS PharmSciTech, 2010
- Development and investigation of gastro retentive dosage form of weakly basic drugAsian Journal of Pharmaceutics, 2010
- Pharmacokinetics and Absorption of Posaconazole Oral Suspension under Various Gastric Conditions in Healthy VolunteersAntimicrobial Agents and Chemotherapy, 2009
- Strategies to Overcome pH-Dependent Solubility of Weakly Basic Drugs by Using Different Types of AlginatesDrug Development and Industrial Pharmacy, 2008
- Posaconazole: A Broad-Spectrum Triazole Antifungal AgentClinical Infectious Diseases, 2007
- HPLC analysis of the antifungal agent posaconazole in patients with haematological diseasesMycoses, 2006
- Preparation and characterization of etoricoxib solid dispersions using lipid carriers by spray drying techniqueAAPS PharmSciTech, 2005